These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35352998)

  • 1.
    Knoll KE; van der Walt MM; Loots DT
    Microbiol Spectr; 2022 Apr; 10(2):e0231521. PubMed ID: 35352998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elucidating the Antimycobacterial Mechanism of Action of Decoquinate Derivative RMB041 Using Metabolomics.
    Knoll KE; Lindeque Z; Adeniji AA; Oosthuizen CB; Lall N; Loots DT
    Antibiotics (Basel); 2021 Jun; 10(6):. PubMed ID: 34200519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An
    Tanner L; Haynes RK; Wiesner L
    Front Pharmacol; 2019; 10():120. PubMed ID: 30833898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical Delivery of Artemisone, Clofazimine and Decoquinate Encapsulated in Vesicles and Their In vitro Efficacy Against Mycobacterium tuberculosis.
    van Zyl L; Viljoen JM; Haynes RK; Aucamp M; Ngwane AH; du Plessis J
    AAPS PharmSciTech; 2019 Jan; 20(1):33. PubMed ID: 30604176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycobacterial DNA Replication as a Target for Antituberculosis Drug Discovery.
    Płocinska R; Korycka-Machala M; Plocinski P; Dziadek J
    Curr Top Med Chem; 2017 Jun; 17(19):2129-2142. PubMed ID: 28137234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug repositioning for anti-tuberculosis drugs: an in silico polypharmacology approach.
    Madugula SS; Nagamani S; Jamir E; Priyadarsinee L; Sastry GN
    Mol Divers; 2022 Jun; 26(3):1675-1695. PubMed ID: 34468898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
    Uddin R; Zahra NU; Azam SS
    Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against
    Venugopala KN; Tratrat C; Pillay M; Chandrashekharappa S; Al-Attraqchi OHA; Aldhubiab BE; Attimarad M; Alwassil OI; Nair AB; Sreeharsha N; Venugopala R; Morsy MA; Haroun M; Kumalo HM; Odhav B; Mlisana K
    Drug Des Devel Ther; 2020; 14():1027-1039. PubMed ID: 32214795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced cellular uptake of a new, in silico identified antitubercular candidate by peptide conjugation.
    Horváti K; Bacsa B; Szabó N; Dávid S; Mező G; Grolmusz V; Vértessy B; Hudecz F; Bősze S
    Bioconjug Chem; 2012 May; 23(5):900-7. PubMed ID: 22515329
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Jagadeb M; Rath SN; Sonawane A
    J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tubercular Modelling via QSAR Approach, In Silico Design and Virtual Docking Screening of Designed Hypothetical Inhibitors Against DNA gyrase Protein.
    Adeniji SE
    Curr Comput Aided Drug Des; 2021; 17(6):739-758. PubMed ID: 32586260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Inhibitors for Mycobacterium Tuberculosis Peptide Deformylase Based on Virtual Screening in Silico.
    Li X; Jiang Q; Yang X
    Mol Inform; 2022 Mar; 41(3):e2100002. PubMed ID: 34708566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel antituberculosis agents among 3-phenyl-5-(1-phenyl-1H-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazole derivatives targeting aminoacyl-tRNA synthetases.
    Rybak MY; Balanda AO; Yatsyshyna AP; Kotey IM; Starosyla SA; Bdzhola VG; Lukash LL; Yarmoluk SM; Tukalo MA; Volynets GP
    Sci Rep; 2021 Mar; 11(1):7162. PubMed ID: 33785838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical Exploration of a Highly Selective Scaffold with Activity against Intracellular
    Njikan S; Ahmed S; Manning A; Awasthi D; Ovechkina Y; Chowdhury S; Butts A; Parish T
    Microbiol Spectr; 2022 Jun; 10(3):e0116122. PubMed ID: 35612308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Energy Metabolism in
    Bald D; Villellas C; Lu P; Koul A
    mBio; 2017 Apr; 8(2):. PubMed ID: 28400527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.